Casma Therapeutics Nominates First-in-Class TRPML1 Agonist CSM-101 for Parkinson's Disease Treatment
Key Insights
Casma Therapeutics (search) has nominated CSM-101 (search), a first-in-class TRPML1 (search) agonist, as its lead development candidate for treating Gaucher's disease (search) patients with Parkinson's disease (search).
Preclinical studies demonstrate CSM-101 (search)'s ability to restore lysosomal function, reduce toxic alpha-synuclein (search) levels, and preserve dopaminergic neurons in multiple disease models.
The company plans to file an Investigational New Drug application with the FDA in the first half of 2026, targeting genetically defined patient populations initially.
Casma Therapeutics (search) has nominated CSM-101 (search), a first-in-class TRPML1 (search) agonist, as its lead development candidate for treating neurodegenerative diseases, marking a significant milestone in targeting lysosomal dysfunction through a novel therapeutic approach. The Cambridge-based biotechnology company announced the nomination on June 5, 2025, positioning CSM-101 for initial development in Gaucher's disease (search) patients with Parkinson's disease (search) (GD-PD), with potential expansion into GBA-associated Parkinson's disease (search) (GBA-PD) and broader Parkinson's disease populations.
Novel Mechanism Targets Lysosomal Dysfunction
CSM-101 (search) represents a highly differentiated, orally bioavailable small molecule that restores lysosomal function by activating TRPML1 (search), a critical lysosomal ion channel. TRPML1 regulates essential aspects of lysosomal function, including lysosomal pH and cellular waste clearance. Dysfunction of this channel leads to impaired degradation and accumulation of toxic substrates, contributing to the pathology of neurodegenerative and lysosomal storage diseases.
"Our nomination of CSM-101 (search) marks a major milestone for Casma and the field as we translate our deep expertise in autophagy and lysosomal biology into therapeutic candidates," said Frank Gentile, Ph.D., Chief Executive Officer of Casma Therapeutics (search). "Our preclinical data demonstrate that activating TRPML1 (search) effectively addresses lysosomal dysfunction, a central driver in both rare and prevalent neurodegenerative diseases."
Promising Preclinical Results Across Disease Models
In preclinical studies, CSM-101 (search) demonstrated high CNS exposure and potent activity across clinically relevant models. The compound showed significant reductions in toxic lipid levels, decreased neuroinflammation, and improved survival in multiple Gaucher's disease (search) models. In GBA-associated Parkinson's disease (search) and idiopathic Parkinson's disease (search) models, CSM-101 reversed pathological phenotypes, lowered toxic alpha-synuclein (search) levels, and preserved dopaminergic neurons, supporting its potential as a disease-modifying therapy.
These results are particularly significant given the genetic connection between Gaucher's disease (search) and Parkinson's disease (search). Mutations in the GBA1 (search) gene, which cause Gaucher's disease, are the most common genetic risk factor for Parkinson's disease and disrupt lysosomal homeostasis. Restoration of TRPML1 (search) activity has been shown to correct lysosomal defects in preclinical models across this spectrum of diseases.
Strategic Development Approach
Leon Murphy, Ph.D., Chief Scientific Officer of Casma Therapeutics (search), emphasized the company's targeted strategy: "CSM-101 (search) represents a scientifically validated and targeted approach to restoring lysosomal function through TRPML1 (search) activation, addressing a central driver of disease progression in Gaucher's disease (search) and Parkinson's disease (search). By focusing first on genetically defined patient populations and leveraging robust biomarkers, we are positioned to deliver rapid clinical proof of concept with the potential for meaningful benefits for patients."
The favorable pharmacokinetic and safety profiles observed in preclinical studies, combined with the mechanistic data, provide strong translational rationale for clinical development. Casma plans to file an Investigational New Drug (IND) application with the US FDA for CSM-101 (search) in the first half of 2026.
Broader Platform Potential
Beyond CSM-101 (search), Casma Therapeutics (search) is advancing targeted therapies that engage lysosomal or autophagy systems to selectively degrade disease targets across neurodegeneration, oncology, inflammation, and metabolic disorders. The company's PHLYT™ degrader platform aims to unlock new therapeutic possibilities through selective autophagy-targeted degradation of large, complex disease targets such as organelles, protein aggregates, and signaling complexes.
The company will present preclinical data supporting CSM-101 (search)'s progression into IND-enabling studies at the GBA1 (search) Meeting 2025, taking place June 5-7 in Montreal, Canada, providing the scientific community with detailed insights into this novel therapeutic approach.